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ABSTRACT 
OBJECTIVES: A prospective randomized study was conducted in 72 pregnant 
women, with the gestational period (between 12 and 20 weeks), to compare the 
efficacy and safety of oral versus vaginal administration of misoprostol for second 
trimester pregnancy termination. PLACE & DURATION OF STUDY: The 
Department of Obstetrics and Gynaecology, Govt. Kilpauk Medical College and 
Hospital (KMCH), Chennai from November 2012 and November 2013. 
METHODOLOGY: Women aged 18-38 years requesting MTP for maternal reason, 
fetal congenital anomalies and intrauterine fetal demise were randomly assigned into 
two groups. Group A (n=36) had misoprostol orally while the Group B (n=36) 
received misoprostol by vaginally route. Dosage regimen was similar in both the 
groups that was 200 µg every 4 hrs until the abortion occurred or maximum up to 6 
doses. MAIN OUTCOME MEASURES: Efficacy included induction to delivery 
interval and safety included maternal complications and side-effects like nausea, 
vomiting, diarrhoea, fever and abdominal pain and results were compared. 
RESULTS: The percentage of women who delivered was significantly higher in the 
vaginal group than the oral group (94.44% vs. 66.67%, P<0.03018) within 24 hrs. The 
induction to delivery interval and incidence of side-effects were noted. 
CONCLUSION: Vaginal administration of misoprostol resulted in a higher success 
rate and misoprostol is safe and effective drug for second trimester pregnancy 
termination. 
Key words: Misoprostol, oral and vaginal route, second trimester pregnancy 
termination 
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1. INTRODUCTION 
1.1. ABORTION 
Abortion is theoretically defined as termination of pregnancy before 
the foetus becomes viable (capable of living independently). This has 
been fixed administratively at 28 weeks, when the foetus weighs 
approximately 1000g. Medical abortion is becoming extremely popular 
today. The accepted method of medical abortion worldwide is a 
combination of Mifepristone with the prostaglandin. Unsafe abortion 
results in complications are main public health problems in developing 
countries. Abortion is legal for a wide range of medical and social reasons 
even in our country. 
 Khan et al. 1999
[1] 
 in his study observed that problems such as 
abortion services by trained medical personnel in registered facilities, the 
stigma connected with induced abortion, the threat of forced contraceptive 
acceptance, and low levels of awareness regarding the legality of the 
procedure compel them to undergo illegal abortion under untrained 
practitioners using  unsafe conditions resulting in  chronic reproductive 
tract morbidity such as chronic disability, infertility and infections. 
1.2. INCIDENCE IN INDIA 
According to the Consortium on National Consensus for Medical 
Abortion in India, every year an average of about 11 million pregnancies 
are terminated by medical ground and 20,000 women died every year due 
to abortion-related complications. 
[2] 
 Most abortion-related maternal 
deaths are attributable to illegal abortions. 
[ 3]
 . The number of abortions 
reported includes legal and induced abortions are shown in the following 
table.
[4]
  
Year 1972 1975 1980 1985 1990 
No. of 
abortion 
24300 214197 388405 583704 581215 
 
Year 1995 2000 2003 2007 2010 
No. of 
abortion 
570914 725149 763126 641786 620472 
 
Worldwide 42 million legal abortions and 10 to 12 million 
clandestine abortion take place every year, of which 10 to 15% is 
performed in second trimester. In India alone, 6.7 million induced 
abortions occur annually, of which late abortion constitute 10-7 to 15%
[5] 
1.3. TYPES OF ABORTION 
1.3.1. Induced 
Induced abortion is medically referred to as a therapeutic abortion 
when it is performed to save the life of the pregnant woman and hence the 
physical or mental health of women is not disturbed. It is carried out in 
cases where the child will have a significantly increased chance of 
premature morbidity or mortality or disabled and to avoid the risk of 
multiple pregnancies.  
1.3.2. Spontaneous 
A spontaneous abortion consists of expulsion of the products of 
conception before the fetus is viable i.e upto 28 weeks of gestation. In 
developed countries advanced management in neonatal care can salvage 
some babies at and after 20 weeks of gestation, with the fetus weighing > 
5 gram. Hence, their definition of abortion is limited to 20 weeks of 
pregnancy. 75% abortions occurred in the first trimester and only 25% 
occur in the second trimester. 
The causes of a spontaneous abortion cannot be elucidated in many 
cases, but some well known causes are  (i) Fetal causes: Abnormal 
embryo and blighted ova, accounting for 50% of early abortion,  are 
caused by chromosomal anomalies, such as trisomy, triploidy, Turner’s 
syndrome and autosomal chromosomal abnormalities, which are lethal to 
the growth of the fetus. (ii). Gametes: aging ova and abnormal sperms 
cause poor fertilization, which leads to a blighted ovum. (iii). Placenta: 
Praevia, multiple pregnancy, H. mole and acutehydramnious are well 
known obstetric cause of spontaneous abortion. (iv). Hormonal cause: 
Progesterone deficiency is well known cause of an early abortion. 
Thyrotoxicosis and uncontrolled diabetes may rarely cause a pregnancy 
loss. (v) Nutritional factors, smoking, excessive alcohol consumption: 
These factors contribute to spontaneous abortion. Other causes include 
(vi) Trauma, (vii) Maternal diseases, (viii) Drugs, (ix) Abnormalities in 
the genital tract and (x) Immunological factors.  
1.4. THE MEDICAL TERMINATION OF PREGNANCY ACT 1971 
1.4.1. MTP Act 1971 
   Liberalization of the medical termination of pregnancy Act was 
approved by Parliament in the year 1971 and was implemented in 1972 
and revised in 1975. It was last amended in 2006. It lays down the 
conditions under which MTP can be performed in India. According to the 
act, Medical Termination of Pregnancy in India is allowed up to 20 
weeks. However there is no definitive method for MTP between 13 and 
20 weeks resulting more unsafe abortion during this period. The following 
conditions which warrant termination of pregnancy are stipulated under 
MTP Act 1971:  
a. Medical – where continuation of the pregnancy would endanger 
the life of the pregnant women or cause grave injury to her 
physical or mental health.  
Examples are grade 3 or 4 hypertension, cervical or breast 
malignancy and severe epilepsy. 
b. Eugenic- where substantial risk exist to the child being born 
with some serious physical or mental abnormality. 
c. Social Indications – include pregnancy caused by rape or incest 
or unplanned pregnancy or pregnancy due to contraceptive 
failure  
1.4.2. Conditions 
The written consent of the patient on a special form is necessary 
prior to the procedure.  If the women are less than 18 years of age or she 
is mentally abnormal, the written consent of the legal guardian must be 
obtained. 
1.4.3. Who can perform MTP? 
 Only a registered medical practitioner having post graduate training 
in Obstetrics and Gynecology or who has had special training in MTP can 
perform the procedure.  For termination of pregnancies up to 12 weeks of 
gestation the opinion of one registered medical practitioner is enough. 
However, in the case of second trimester MTP, the opinion of two 
registered medical practitioners is essential. 
1.4.4. Where can MTP be performed?  
 According to the act, MTP can be performed only in a hospital 
established and maintained by the government or in a place recognized 
and approved by the government for this purpose. Abortion services 
should be provided in strict confidentiality.  
1.4.5. Benefits of the MTP Act 
The incidence of septic abortion has definitely come down the 
following the liberalization of abortion. Though MTP does indirectly 
promote family planning, repeated abortions are detrimental to a women’s 
health and hence MTP should not be considered as a family planning 
method. It is imperative that women undergoing MTP be counseled about 
the available contraceptive methods.
 [5]
 
1.5. METHODS OF MTP 
Methods of MTP can be broadly classified as follows: 
1.5.1. Methods of first trimester MTP 
 Menstrual regulation 
 Dilatation  and suction evacuation 
 Cervical softening prior to dilatation and suction evacuation 
1.5.2. Methods of second trimester MTP 
 Surgical evacuation 
 Extraovular instillation of drugs 
 Extrauterine methods 
The above methods are used singly or in combination. The second 
trimester abortion is associated with more risks than a first trimester 
procedure and hence should not be under taken lightly. The opinion of 
two registered medical practitioners is essential before performing a 
second trimester abortion. An ultrasound is a good prerequisite especially 
to confirm and document the gestational age. The upper limit is 20 weeks.  
The oxytocic drugs stimulate myometrial activity and shorten the 
induction-abortion interval in the second trimester. Similarly, the use of 
prostaglandins (gel, suppository) a few hours prior to the procedure helps 
to attain a gradual softening and atraumatic dilatation of the cervix, 
facilitating further dilatation and evacuation procedures. The incidence of 
second trimester MTP has drastically come down and is mainly employed 
today for fetal malformations.  
1.5.2.1. Medical methods 
Prostaglandins 
 Prostaglandins have been used by various routes: orally, vaginally, 
intramuscularly, intra-amniotically, and extra-amniotically. Natural 
prostaglandins and prostaglandins analogues have been used. Recently 
very good success rates are being obtained with the use of PG E1 
analogue, misoprostol. 400 µg vaginally, 3 doses and 3 hrs apart have 
been shown to give good results and is usually the first choice. Various 
other doses and regimens are also being tried. 
Mifepristone and misoprostol 
 This combination is also being studied and showing promise. 200 
mg mifepristone followed 48 hrs later by 600 µg of misoprostol vaginally 
and then by 400 µg misoprostol vaginally every 3 hrs is one regime. 
There are various other regimens are being tried.  
 
Ethacridine lactate or Emcridil 
 Ethacridine lactate has been used extra- amniotically for a very 
long time and is shown to be safe and effective. The side effects are also 
minimal. It works by the release of prostaglandins from the decidua. 10 
ml of 0.1 % ethacridine is used for each gestational week up to a 
maximum of 150 ml. It is introduced extra-amniotically by means of a 
Foley catheter. Oxytocin can be used for augmentation and to reduce the 
induction delivery interval. In case of failure, reinstallation can be tried. 
 
Hypertonic saline and urea 
These were being used intra-amniotically previously. Hypertonic 
saline was associated with maternal deaths and thereby has been largely 
abandoned in most countries. The main complication of saline are 
haemorrhage, infection and hyper natremia. Disseminated intra vascular 
coagulation is another rare albeit serious complication. 
 
 
1.5.2.2. Surgical method 
Dilatation and evacuation 
This can be used up to 16 weeks but requires cervical dilatation 
with the help of laminaria tents or vaginal misoprostol. Evacuation is done 
using ovum forceps.  Once the evacuation is complete, suction evacuation 
and if necessary a curettage can be done to ensure completeness of the 
procedure. The complications are similar to those following first trimester 
evacuation. 
Hysterotomy 
This involves the removal of the fetus through an incision in the 
lower segment as in caesarean section. After opening the abdomen, the 
uterovesical fold of peritoneum is divided and the bladder pushed down. 
If possible, a transverse incision is made, but sometimes a vertical 
incision may be necessary. The fetus is removed and the incision closed in 
two layers. If needed, sterilization can be done at the same time. 
Hysterotomy is almost never performed as a primary procedure, but only 
when all other methods have failed. 
 
 
Hysterectomy  
This is also never done as a primary procedure except if there is a 
co existing problem like cancer cervix.  
The currently used first line methods for second trimester abortions 
are misoprostol alone or with mifepristone 
[6,7]
.  
1.5.2.3. Other Methods 
There are number of methods using herbs in folk medicines such as 
black cohosh, pennyroyal and the new extinct silphium. The side-effects 
cannot be ruled out in the practice and thus it is not legally recommended. 
1.6.  MISOPROSTOL 
1.6.1. Pharmacology 
 Misoprostol is a synthetic analog of prostaglandin E1. It is used in 
prevention of gastric ulcers induced by non-steroidal anti-inflammatory 
agent. In addition, it has been used in the treatment of duodenal or gastric 
ulcer. It is an important drug in Obstetrics and Gynecology practices 
because of its priming action on uterus and cervix. The clinical 
application of misoprostol as follows: 
 Medical Abortion 
 Induction of labor 
 Cervical priming before surgical procedure 
 Medical evacuation for miscarriages and  
 Management of postpartum hemorrhage 
1.6.2. Structure of misoprostol 
 Misoprostol was registered in 1986 for the prevention and treatment 
of peptic ulcers resulted from Non-Steroidal Anti-Inflammatory Drugs 
(NSAID). It is safe and well tolerated within the recommended dose of 
800 µg per day. The Prostaglandin E series (naturally occurring) was 
discovered by Robert et al in the year 1967. 
[8] 
The E series have three 
drawbacks that stalled their clinical application: 
 Several side-effects 
 Chemical volatility leading to a short shelf life and  
 Rapid metabolism resulting in a lack of oral activity and it had 
short duration action when given parenterally.   
 Figure 1. PGE1 Analog – Misoprostol. 
Misoprostol is available in many countries worldwide and has 
advantages over the rest of the prostaglandins as it is inexpensive, thermo 
and light stable and has shelf life of several years even in tropical 
conditions and is easy to use. Its action upon the contractility of 
myometrium is extensive and is very efficient in dilating the cervix. It 
can be used alone or with combination of Mifepristone 
1.6.3. Route of Administration 
The routes of administration of Misoprostol are 
 Oral 
 Buccal 
 Sublingual 
 Vaginal 
 Rectal. 
1.7. ADVERSE REACTION OF MISOPROSTOL 
The most common side-effects after administration of misoprostol are   
 Vomiting 
 Abdominal pain 
 Headache 
 Chills 
 Fever 
 Shivering 
 Diarrhea 
 
 
 
 
 
 
 
 
 1.8. AIM AND OBJECTIVES OF THE STUDY 
Considering the merits of misoprostol and its beneficial effect on 
uterus and cervix to expel the fetus under MTP, the present study was 
under taken in the Department of Obstetrics & Gynecology, Govt. 
Kilpauk Medical College Hospital, Chennai, with the following 
objectives: 
1. To compare the efficacy and safety of both oral and vaginal 
misoprostol in second trimester pregnancy termination 
2. To study the Induction-abortion interval with misoprostol by oral 
and vaginal route 
 
 
 
 
 
2. REVIEW OF LITRATURE  
 Dickinson JE et al.
[9]
 (1998) conducted a study on 100 women 
found that intravaginal  misoprostol was as effective as gemeprost in 
achieving delivery within 24 hours (alpha = 0.1, 80% power) in second-
trimester pregnancy. Women with fetal death in utero, severe fetal 
anomaly, or psychosocial pregnancy termination between 14 and 28 
weeks gestation were recruited and randomized to receive either 1 mg 
gemeprost 3 hourly for 5 doses, or 200 mcg misoprostol 6 hourly for 4 
doses, intravaginally . Delivery within 24 hours occurred in 75.1% of 
women receiving gemeprost and 74.9% receiving misoprostol (P = 
1.0).There was no significant difference in the incidence of maternal fever 
> 37.5 degrees C, nausea, diarrhea, or placental retention. A 200-fold 
pharmaceutical cost advantage was observed with the use of misoprostol 
compared with gemeprost. Intravaginal misoprostol performs as 
effectively as gemeprost in achieving delivery in the second trimester 
without increase in adverse effects and displaying a significant cost 
advantage. 
Carbonell JL et al.
[10]
 (1998) demonstrated in their study the 
effectiveness and safety of misoprostol without the need of post-expulsion 
systematic curettage in early second-trimester abortions, i.e. at 13-15 
weeks' gestation. A group of 151 women, with gestations from 85 to 105 
days, received 800 micrograms of vaginal misoprostol every 25 h for a 
maximum of three doses, without having post-expulsion systematic 
preventive curettage performed. A complete abortion occurred in 121/151 
subjects (80%; 95% confidence interval, 78-87%). The decrease in 
hemoglobin was statistically significant (p = 0.0001), but without clinical 
relevance (11.8 mg/dl (SD, 0.9) before treatment and 11.4 mg/dl (SD, 1.0) 
afterwards. No statistically significant differences were found between the 
success rate and any of the women's characteristics. Vaginal bleeding 
lasted 6 +/- 3 days, spotting 6 +/- 3 days, and total bleeding 12 +/- 5 days 
(median, 11 days; range, 1-29). The acceptable expulsion time in 80% of 
the cases, the fact that post abortion systematic curettage was not needed, 
the clinically insignificant hemoglobin loss and the abortion rate obtained, 
show that misoprostol by vaginal administration may be an alternative for 
interrupting gestation in the early second trimester of pregnancy.  
Suk Wai et al.
[11]
 (2000) included a total population of 142 healthy 
patients and randomly assigned into two groups, group 1 received 200 mg 
mifepristone plus 400 μg  misoprostol orally every 3 hrs upto the 
maximum dose of 5 doses. Group 2 received 200 mg mifepristone plus 
200 μg  misoprostol vaginally every 3 hrs upto the maximum dose of 5 
doses. In their study, it found that the rate of complete abortion was 
81.40% in the oral group  and 75.40%  in the vaginal group.  The 
complete abortion rate in the vaginal group was insignificant than oral 
group. The median induction to abortion interval was similar in both the 
groups  i.e. 10.40 versus 10.0 hrs. Both the occurance of diarrhoea [40.0 
(oral) versus 23.20% (vaginal), p value =0.03] and the amount of drug 
used in this study (1734 compared with 812, P<0.0001) were significantly 
higher in the Group 1 (oral) than in the vaginal group. The percentage of 
women who aborted in 24 h was found to be 81.4% in the oral group and 
87.0% in the vaginal group.  
Wong  KS et al.
[12]
 (2000) in their study 148 randomly selected 
women aged 16-40 years were given vaginal misoprostol 400 microg 
every 3 h for a maximum of five doses in 24 h for group 1. Women in 
group 2, were given vaginal misoprostol 400 microg every 6 h for a 
maximum of three doses in 24 h. The same regimen was repeated if 
women did not abort in 24 h. The median induction-abortion interval was 
found to be 15.2 h and 19.0 h in  group 1 and group 2 respectively and it 
was observed in their study that the median induction to abortion interval 
was significantly very shorter, p < 0.01, than that in the group 2 (vaginal). 
The pregnant women in the study who achieved the successful abortion 
was 90.50%  and 75.70% within 48 hrs  for group 1 and group 2, 
respectively. It is found that the rate of successful abortion in group 1 was 
also significantly higher (<0.02) than that in the group 2. 
 Gilbert A et al.
[13]
 (2001) conducted a trail study to evaluate the 
safety and efficacy of misoprostol  in termination of mid trimester 
pregnancy by selecting a population of 55healthy pregnant women. Of the 
55 cases, 26 women received all dose of misoprostol orally and 29 
received vaginal route. The regimen of misoprostol dose was 400 µg a the 
first dose followed by a second dose of 200 µg 2 h later and then 40 h 200 
µg doses until delivery or 32 h from commencement of the treatment. The 
average induction-delivery interval in the vaginal group was 17.5 hrs 
compared to 33 hrs in the oral group (p=0.0003). The percentage of 
women who delivered at 24 h was 93% and 19% for the vaginal 
administration group and oral administration group, respectively. At 48 
hrs, the percentage of women who delivered was 100% and 70% for the 
vaginal administration group and oral administration group (p <0.05), 
respectively. 
Pongsatha S and Tongsong T 
[14]
 (2001) in their study administered 
800 microgram misoprostol tablet intravaginally every 12 hours. The 
mean induction delivery time was 21.38 + 13.68 hours, mean abortion 
time was 21.56 +/- 13.68 hours. Diarrhea was the most common side 
effect occurring in 40 per cent of patients.  
Dickinson JE et al. 
[15]
 (2003) conducted an MTP study to compare 
the clinical efficacy and side effects of oral misoprostol with vaginal 
misoprostol for second-trimester pregnancy termination on a sample size 
of 225 women. Three misoprostol regimens were compared: 400 microg 
vaginally at 6-hour intervals (group 1), 400 microg orally at 3-hour 
intervals (group 2), and a loading dose of 600 microg vaginally followed 
by 200 microg orally at 3-hour intervals (group 3). There was a significant 
difference in the median time to achieve delivery among the three groups: 
group 1, 14.5 hours (95% confidence interval 12.0, 16.9), versus group 2, 
25.5 hours (13.5, 23.8), versus group 3, 16.4 hours (interquartile range 
14.2-37.3) (P =.042). Within 24 hours of commencement 85.7% of 
women in group 1, 44.8% in group 2, and 74.1% in group 3 delivered (P 
=.003). At 48 hours 0% in group 1, 20.7% in group 2, and 3.7% in group 
3 were undelivered (P =.011). 
Suneeta Mittal et al. 
[16]
 (2005) in their  trial study, 150 healthy 
pregnant women of  < 63 days of amenorrhoea received mifepristone (200 
mg) orally on day one and followed by misoprostol 0.80 mg orally and 
vaginally on day three. In their study, it was seen that the rate of 
completion abortion rate in each groups was 96 to 100% and further 
noticed that there was no further increasing successful outcome  and  
shortening of duration or amount of bleeding  when extra dose of 0.40 mg 
misoprostol twice a day from day four to ten was adminstered. 
Pongsatha S and Tongsong T [17] (2004) observed in their study that 
the success rates of termination in pregnancy within 12, 24, 36, 48 hrs 
were 50.80%, 84.10%, 88.90% and 92.10% respectively when the  
regimen of 400 μg of  misoprostol was given intravaginally at every 6 hrs. 
In their study, the mean induction to delivery time in cases of delivery 
within 48 hrs was 13.2 ± 8.4 hrs, the range was 2.25-22.9 hrs. The most 
frequent maternal side-effect was chill (33.3%). No serious maternal 
complication was detected. 400 μg  misoprostol given orally at every 4 h 
is  more effective for pregnancy termination in cases of intra-uterine fetal 
death and may be an alternative regimen because of its easiness and 
convenience. Time interval to fetal expulsion for misoprostol 
administration was 25.9 +/- 34. 1 hour, the range 4.0-142.7 hours. This 
result reconfirms the efficacy of misoprostol and suggests that 
misoprostol may comparatively be safer even in cases with previous 
cesarean section. The high incidences of adverse reactions were chill 
(23.50%), fever (47.10%) and nausea (17.60%). In this series, no uterine 
rupture occurred at all. 
Subir Kumar Bhattacharyya et al 
[19]
 (2006) observed in their study 
that there was no significant difference in the success rates at 24 and 48 h 
(Regime A: 97.18 and 98.59%; Regime B: 95.45 and 95.45%), and in 
mean induction-abortion interval (12.97 versus 12.13 h). However, mean 
misoprostol requirement was significantly higher for Regime A (1701.4 
versus 1269.7 µg). The incidence of fever was significantly less in 
Regime B (32.4 versus 14.9%). Use of vaginal misoprostol for second 
trimester abortion had comparable efficacy with less drug requirement 
for the 600 µg loading dose followed by 200 µg 3-hourly regimes 
compared to the 400 µg 3-hourly regime. 
Behrashi M et al 
[20]
 2008 observed in their study that the 
percentage of women who delivered was significantly higher in 
vaginal group than the oral group (86.70 versus 43.30 p=0.0006) 
when the initial doses 400 μg was followed by 400 µg up to the 
maximum of 3 doses (1200 μg) was administered both orally 
(Group-1, n=30) and vaginally (Group-2, n=30). In induction to 
expulsion interval and complications rates no significant differences 
were observed.      
Mahjabeen et al 
[21]
 2009 in their study of sixty healthy pregnant 
women at second trimester of gestation found that after oral misoprostol 
Group-1 (n=30) and vaginal misoprostol Group- 2 (n-30) of 200 μg 4 h 
apart. They found the mean induction abortion interval was found to be 
11.80±8.30 and 12.80±8.50 h, respectively for the group 1 and group 2 
patients.  The result obtained in his study was insignificant statistically. 
No reports on the common side effects in both the groups (dizziness, 
nausea, diarrhea, pyrexia and hyper stimulation). 
Helena von Hertzen et al 
[22]
 (2009) in their study selected 
randomly selected 681 healthy pregnant women and administered each 
400 mg of misoprostol vaginally and sublingually every 3 hrs up to the 
maximum of 5 doses. They further administered a quantity of 400 mg 
misoprostol every 3 hrs up to 5 doses, if abortion did not take place at 24 
hrs. In their study, it was noted that at 24 hrs, the success (complete or 
incomplete abortion) rate was 85.90% in the vaginal administration group 
and 79.80% in the sublingual group, respectively. The study concluded 
that higher effectiveness was seen in vaginal administration than 
sublingual administration of misoprostol in termination of second 
trimester pregnancies, but the results in their study were mainly 
determined by nulliparous women. 
Sumant R. Shah et al 
[23]
. (2010) conducted a study in order to find 
out the safety and effectiveness of vaginal misoprostol for second 
trimester termination of pregnancy. It was a prospective study involving 
30 women with 12-20 weeks gestation requesting termination. Four 
hundred microgram misoprostol was inserted in the vagina followed by 
200μg every four hourly. The mean age of the women was 25.96 years. 
The mean gestational age was 15.66 weeks. Chi-square test was used for 
statistical analysis. 93.3% of women aborted within 16 hours without any 
significant side effects. Vaginal misoprostol is a very effective and safe 
method for second trimester pregnancy termination. It reduces the time 
and the cost of second trimester pregnancy termination.  
Deshpande Sonali et al. 
[24]
. (2010)  in their study demonstrated that 
200 healthy women within 63 days of amenorrhea were selected for 
medical abortion and administered 200 mg of mifepristone. After 48 h, 
they were administered misoprostol 400 µg vaginally. At the end of 4 
h, reinstallation of misoprostol 400 mg was given vaginally 
whenever required.  The complete abortion rate in pregnant women 
with amenorrhea ≤49 days versus 50-63 days was 99.16% and 
98.75%, respectively. The average duration of bleeding in women 
with amenorrhea ≤49 days versus 50-63 days was 6.26 (S.D. 2.43 
days) and 6.98 days (S.D. 2.26 days), respectively and the difference 
of both the groups was statistically significant (p <0.05). The study 
has confirmed that the use of the above combination was safe and 
effect for inducing medical abortion in pregnant women with 
amenorrhea up to 9 weeks gestation (63 days). 741 pregnancy 
terminations were carried out using misoprostol with dosage varied 
from 50 µg to 800 µg, mostly 400 µg intravaginal route every 3 h. 
The most common incidence of side effects for termination of 
pregnancy was severe thalassemia (35.80%). The majority of cases 
in the study were pregnancies with live fetus and 18.20% were linked 
with dead fetus in utero. The success rate of pregnancy termination 
within 48 h was 85.90%. The pregnant women with previous 
cesarean section accounted for 8.6% of cases. The mean abortion 
time and gestational age was 25.35 h (ranging from 1.25 to 
247.888h) and 20.94 weeks, respectively. Two most common 
adverse effects in the study were fever and chill (34.30% & 43.70%). 
There was no adverse complications (uterine rupture) were found. 
The study finally concluded that misoprostol had high efficacy for 
the termination of pregnancy with acceptable minor side effects and 
it was relatively safe.  
Pongsatha and Tongsong (2011) 
[25]
 found the most common 
complications to be chill (43.7%), analgesic-requiring pain (39.3%) and 
fever (34.3%) in their patients who received 400 μg misoprostol through 
the intravaginal route every 12 h. High doses (800 μg in 24 h) may have 
affected the higher complication rates. 
Anupama Goel et al 
[26]
 (2011) in their study found that eighty 
eligible healthy women were selected with single intrauterine pregnancy 
of more than ≤ 7 weeks of gestation. They administered 200 mg of 
mifepristone orally and 400 μg of misoprostol vaginally simultaneously in 
Group 1 and Group 2, respectively at 24 hr interval. The rate of complete 
abortion was 95% and 97.50% for 38 women in (Group 1) and 39 women 
(Group 2), respectively. The induction abortion interval of Group 1 and 
group 2 was 6.50 ± 1.48 and 5.95 ± 1.81 h, respectively. The p value for 
the rate of complete abortion and the induction abortion interval was 
p=0.56 and p=0.13, respectively.  The combined administration of 
mifepristone and misoprostol (400 μg) vaginally is very effective 
alternative to standard regimens for medical abortion was up to 7 weeks 
of gestation period. 
Nagaria Tripti et al 
[27]
 (2011) conducted a study on the safety and 
efficacy of misoprostol alone and mifepristone with misoprostol in second 
trimester pregnancy termination by selecting a population of 200 healthy 
pregnant women. They divided the 200 cases in two groups of 100 each. 
In the study group, 200 mg of mifepristone was given at every 12 h hrs 
before intravaginal insertion of misoprostol 600 μg followed by 400 μg 
misoprostol every 3 hrs up to the maximum interval of 5 doses or till the 
abortion occurs. In their study, it is found that in both groups,  the side 
effects were similar  noted in both the groups were similar for the most 
part of vomiting, fever, nausea, abdominal cramps. The mean induction 
abortion interval from the insertion of the first misoprostol was 
significantly shorter in the pretreated group (mifepristone)  6.72 plus or 
minus 2.26 h  as compared to misoprostol alone group (12.93 ± 3.4 h), the 
p value of the study was P\0.001.  
Sumera Tahir et al 
[28]
. (2011) carried out a study to compare the 
efficacy & safety of Misoprostol for termination of pregnancy in second 
trimester in scarred versus unscarred uterus. During 6 months period from 
22
nd
 March 2007 to 22
nd
  September  2007.  60 patients (30 with scarred 
and 30 with unscarred uterus) were admitted for second trimester 
termination of pregnancy for maternal reason, fetal congenital anomalies 
and intrauterine fetal demise and induced with vaginal misoprostol. The 
loading dose of 400 mcg followed by maintenance dose of 200 mcg at 4 
hourly interval to a maximum of 4 doses.  Efficacy included induction to 
delivery interval & safety included maternal complications and side 
effects like uterine rupture, hysterectomy, severe haemorrhage, pyrexia, 
nausea & vomiting.  Success rate of T.O.P. was 96.7% in group A 
(scarred uterus) VS 93.3% in group B (unscarred uterus) Maternal 
complications were nausea & vomiting 3.3% in group A VS 0% in group 
B, Pyrexia 3.3% in each group, no case of uterine rupture was recorded. 
Misoprostol is safe and effective drug for Midtrimester T.O.P. in scarred 
as well as unscarred uterus.  
Krishna Dahiya et al 
[29]
. (2012) conducted a study on a population 
of 100 pregnant women having gestational age >56 days and divided the 
groups randomly into Group A and Group to study the safety and efficacy 
of mifepristone and buccal misoprostol versus buccal misoprostol alone. 
In Group A , on day 1, women received 200 mg mifepristone followed by 
buccal misoprostol 800 µg on day 2. . In Group B, on day 1, women 
received 800 µg  buccal misoprostol only on day 2. In their study, the rate 
successful abortion in group A and Group B was 92% (n=46) and 74% 
(n=37), respectively. The percentage of incomplete abortion with retained 
products of conception in Group A patients and Group B was 8% (n=4) 
and 16% (n=16), respectively. The 6% (n=3) of pregent women had 
missed abortion and 4% (n=2) had continued pregnancy in Group B 
whereas in Group A none of the women had missed abortion and 
continued pregnancy.  The acceptance of overall method and overall route 
was 100% and 83% respectively. The regimen of misoprostol alone was a 
very low cost and compared to that of mifepristone / misoprostol. Though 
the safety and efficacy of mifepristone followed by buccal misoprostol is 
better, buccal misoprostol alone can be used for termination of pregnancy 
in patients where mifepristone is either unavailable or contraindicated. 
A study conducted by Murat Bozkurt et al 
[30]
. (2012) involved an 
investigation of the effectiveness and complications of oral and vaginal 
misoprostol use on the termination of second trimester pregnancies. A 
total of 103 cases were recruited from the medical records of the 
Gynecology and Obstetrics Clinic of Taksim Research and Training 
Hospital and Şırnak İdil State Hospital. Women underwent therapeutic 
termination of pregnancy between the 14 to 28th week of gestation using 
the defined combined misoprostol regimen. After the women were 
admitted, 200 μg vaginal (100 μg intracervical, 100 μg into the posterior 
fornix), 200 μg oral doses and 200 μg of sequential doses were 
administered in the 2nd and 4th hour. Subjects were excluded from the 
study if they were out of the defined gestational weeks using additional 
drugs with misoprostol; their data has not been recorded in detail. Of the 
103 cases, 86 had an abortion within 24 h and the mean expulsion time 
was calculated as 15.42 ± 7.14 h (min 6.39 to max 20.03) in this group. 
The success rate for the 24 h was found to be 83.4%. Six more cases had 
an abortion when the second dose was given. The mean expulsion time 
was found to be 9.31 ± 3.26 h (min 6.45 to max 13.21) for the second 24 
h. The success rate over 48 h rose to 89.3%. The total expulsion time was 
18.30 ± 8.74 h. There was a history of previous caesarean sections in 2 
out of 11 cases that did not have an abortion and one of these cases 
underwent a hysterotomy. The pregnancy was terminated by evacuation 
and curettage, as abortion did not occur despite 3 different high dose 
misoprostol regimens as in the other cases. Pregnancies of the remaining 9 
cases were terminated with different misoprostol doses, oxytocin infusion 
and the evacuation and curettage method. of the 103 cases, 86 had an 
abortion within 24 h and the mean expulsion time was calculated as 15.42 
± 7.14 h (min 6.39 to max 20.03) in this group. The success rate for the 24 
h was found to be 83.4%. Six more cases had an abortion when the second 
dose was given. The mean expulsion time was found to be 9.31 ± 3.26 h 
(min 6.45 to max 13.21) for the second 24 h. The success rate over 48 h 
rose to 89.3%. The total expulsion time was 18.30 ± 8.74 h. There was a 
history of previous caesarean sections in 2 out of 11 cases that did not 
have an abortion and one of these cases underwent a hysterotomy. The 
pregnancy was terminated by evacuation and curettage, as abortion did 
not occur despite 3 different high dose misoprostol regimens as in the 
other cases. Pregnancies of the remaining 9 cases were terminated with 
different misoprostol doses, oxytocin infusion and the evacuation and 
curettage method. When complication rates were evaluated, analgesic 
requiring pain (18.4%) was the leading complication, followed by nausea 
(11.6%), fever (7.7%), headaches and dizziness (5.8%), transfusion-
requiring haemorrhage (3.8%) and diarrhea (1.9%). Uterine rupture or 
death did not occur. A combined misoprostol regimen is relatively safe 
with acceptable side effects when used carefully for the termination of 
second trimester pregnancies.  
Sonal Kumar et al 
[31]
. (2013) undertook a study to determine the 
efficacy and the side effect profile of a regime of 200 mg of mifepristone 
administered orally followed by 800 mcg of vaginal misoprostol after 
48 h. 50 cases of medical abortion meeting the inclusion criteria were 
included. On day 1, 200 mg of oral mifepristone was given. On day 3, the 
patient was called back, and 800 mcg of Misoprostol administered per 
vaginum and was observed for 6 h. The patients were then called back for 
review after two weeks to make sure that the abortion was complete. 
Although, in most cases, this was clinically evident, an ultrasonography 
was repeated to confirm the completion. Out of the 50 patients, four were 
lost to follow up, and of the remaining 46 patients, abortions were 
complete in 44 (95.65 %), while two (4.35 %) patients required surgical 
intervention. Medical abortion with 200 mg oral mifepristone and 800 
mcg vaginal misoprostol is an effective, safe, reliable, and noninvasive 
method with a success rate of 95.65 %. The availability of this low-cost 
medical treatment using agents which do not require special cold storage 
and transport facilities and negligible operating theater time makes this 
provision of safe abortion feasible in settings especially of developing 
countries, like India, where medical facilities are limited. 
Kranti K. Kulkarni et al 
[32]
. (2013) studied the efficacy and safety 
of combining mifepristone before misoprostol use in second trimester to 
considerably reduce the induction–abortion interval with the lowest 
possible dose and adverse reaction. A prospective study was conducted 
which included 60 patients visiting the antenatal OPD for 
elective abortions between 13 and 20 weeks of gestation as per the MTP 
act. They were randomly divided into two groups of 30 each—the study 
group received mifepristone 200 mg orally before misoprostol, whereas 
the control group was induced with misoprostol alone. The results were 
analyzed. Statistical analysis of the study was done using χ2 test. The 
induction–abortion interval was significantly shorter in the study group, 
thereby decreasing the side-effects of the drug as well as duration of 
hospital stay. 
 
 
 
 
 
3. MATERIALS AND METHODS 
3.1. STUDY DESIGN 
Randomized prospective study of seventy two healthy women, 
between age 18 and 38 years, with 12-20 weeks of pregnancy, requesting 
second trimester termination of pregnancy, were admitted in Department 
of Obstetrics and Gynaecology, Government Kilpauk Medical College, 
Chennai 
  
3.2. STUDY AREA 
The study was conducted in the Department of Obstetrics and 
Gynecology, Govt. Kilpauk Medical College (KMC), Chennai. 
3.3. STUDY PERIOD 
 The study was conducted between November 2012 and November 
2013.  
 
3.4. SAMPLE SIZE 
 Population size (for finite population correction factor or fpc)(N) 
500 
 
 Hypothesized % frequency of outcome factor in the population 
(p):5%+/-5 
 
 Confidence limits as % of 100(absolute +/- %)(d): 5% 
 
 Design Effect (for cluster surveys-DEFF): 1 
 
 Equation for Sample Size n = [DEFF*N p(1-p)]/ [(d2/Z21-α/2*(N-
1)+p*(1-p)] 
 
 For a confidence limit of 95% the sample size is 64, hence the 
sample size was selected as 72. 
 
3.5. SELECTION OF CASES  
Seventy two healthy women, between age 18 and 38 years, with 12-
20 weeks of pregnancy, requesting second trimester termination of 
pregnancy, were included in this study. The indications for termination 
were in consonance with the MTP Act. Written informed consent was 
taken from all the women. Sonography was done in women whenever 
necessary for deciding maturity of the fetus. Ethical clearance was 
obtained from the hospital ethical committee in July 2013. The schematic 
diagram for participants is shown in Fig. 2.  
 
                       
 
 
 
 
                                         
   
 
 
 
 
 
 
 
Figure 2. The schematic diagram of the trial profile 
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3.5.1. EXCLUSION CRITERIA 
a. Women with baseline hemoglobin <8gm/dl. 
b. Maternal local or systemic infection. 
c. Maternal respiratory disease, liver or kidney disease  
d. CVS disease. 
e. Severe Bronchial Asthma 
f. Chronic adrenal failure or steroid therapy 
g. Uncontrolled seizure disorder  
 
3.5.2. INVESTIGATION 
The following investigations were done prior to misoprostol 
administration. 
1. CBC 
2. RFT 
3. Urine routine 
4. Blood group 
5. USG 
6. BT and  
7. CT  
8. VDRL 
9. HIV 
10. HBS Ag 
 
3.6. STUDY GROUP 
 The patients were randomly allocated to Group A (n=36) who 
received oral tablet misoprostol and Group B (n=36) who received 
vaginal tablet misoprostol.   
 
3.7. PROCEDURE OF MISOPROSTOL USE 
A total of 72 cases between 12 and 20 gestational weeks who had 
undergone for medical abortion by using the defined misoprostol regime 
were included in the study. The misoprostol regimes were given in the 
hospital. The patients allocated to Group A, misoprostol 200 µg (Zytotec) 
was given orally every 4 hrs until the abortion occurred or maximum up 
to 6 doses. Doses administered through the oral route were observed. The 
expulsion rate of this regimen at different time intervals [<24 hrs (4-6 h, 
6-8 h, 8-10 h, 10-12 h, 12-16 h and 16-24 h) and <48 h)] and 
complications were investigated. The incidence of side-effects, vital signs, 
amount of bleeding and uterine contractions were investigated every 3 
hrs. The pelvic examination was done every 3 hrs. The gestational weeks 
of the patient were calculated based on the first day of the last menstrual 
period. The calculated gestational weeks were confirmed with 
ultrasonography. A second course of misoprostol was administered if 
abortion did not happen after 24 hrs. After the abortion process was 
complete, pervaginal examination and ultrasonography was done to rule 
out any retained products and confirm the completion. 
For patients in Group- B, misoprostol 200 µg (Zytotec) were 
vaginally administered every 4 hrs till the expulsion of fetus or up to a 
maximum of 6 doses. Doses administered through the vaginal route were 
noted. Vaginal misoprostol was soaked in saline solution and 
administered to the posterior fornix and intracervical region. The 
management and observation of the subjects were followed as in case of 
the procedure followed for Group-A.  
Information about side effects was taken from each woman 
including nausea, vomiting, diarrhoea, fever and abdominal pain. The 
expulsion rates were evaluated at the <24 h and <48 h.  After the passage 
of abortus, check curettage was carried out in all women in a routine 
manner under sedation. Procedure related complications like uterine 
perforation, cervical tear or laceration were noted in few women. 
Perforation was due to uterine curettage. There was no case of rupture 
uterus. All the women were kept in hospital for 24 hours under 
observation. Those who were willing for permanent sterilization were 
considered for laparoscopic tubal ligation. On discharge they were asked 
to come for follow- up after a week or earlier if need arises. On follow up, 
a pelvic examination was performed on all the women. Any abnormal 
bleeding or delayed side effects were also enquired. 
3.8. EFFICACY OF MISOPROSTOL 
The induction- expulsion (abortion) interval was defined as ―the 
interval between the time of administration of the first dose of misoprostol 
to the time when the fetus aborted‖.  
The complete abortion was defined if fetus and placenta was 
expelled completely without resorting to further surgical or medical 
means. 
The rates of successful abortion after initial misoprostol 
administration, induction – expulsion interval, the incidence of side 
effects and complete abortion in both the groups, oral and vaginal were 
tabulated, compared. The results were statistically analyzed and evaluated 
using  Fisher’ exact test (Open Epi programme, Version 2.3, 2009). 
 
4. RESULTS 
A total of 72 women with gestation between 12 and 20 week who 
needed second trimester termination of pregnancy, were included in the 
present study. The two groups of 36 women each were compared for 
various characteristics such as age, parity, previous MTP and LSCS and 
duration of amenorrhea. 
4.1. AGE DISTRIBUTION OF PREGNANT WOMEN 
Table 1 shows age distribution of pregnant women in the age group 
ranged from 18 to 38 years. The maximum number of women was found 
in the age group 26-30 (41.6%) and 21-25 (44.4%) for oral (Group A) and 
vaginal (Group B) route of administration, respectively. The minimum 
number of women was seen in the age group >35 years (2.7%) both for 
oral and vaginal route of administration. The mean age of women was 
26.13 years for Group A and 25.15 years for Group B.  
 
 
 
 
Table 1. Age distribution of pregnant women 
Age in years Number (%) 
Group A (n=36) Group B (n=36) 
<20 03 (8.3%) 04 (11.1%) 
21-25 13 (33.3%) 16 (44.4%) 
26-30 15 (41.6%) 13 (33.3%) 
31-35 04 (11.1%) 02 (5.5%) 
>35 01 (2.7%) 01 (2.7%) 
Mean Age (years) 26.13 25.15 
 
 
 
Figure 3. Age distribution of pregnant women 
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4.2. DEMOGRAPHIC DATA OF PREGNANT WOMEN 
Table 2 shows that the maximum number of women was 
multiparous 77.7% for Group A and 66.6% for Group B. The number of 
women who had previous MTP for Group A and Group B was found to 
be 28 11.11% and 8.3%, respectively. In Group A only one woman 
(2.7%) was found to have undergone LSCS.   
Table 2. Demographic profile of pregnant women 
Parameter Group A (n=36) Group B (n=36) 
Parity No. (%)   
Primi 08 (22.2%) 12 (33.3%) 
Multi 28 (77.7%) 24 (66.6%) 
Previous MTP 04 (11.11%) 03 (8.3%) 
Previous LSCS 01(2.7%) 0 (0%) 
 
 
Figure 4. Demographic profile of pregnant women 
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Table 3 shows that the maximum number of women was found to 
be 11 (30.5%) in the gestation period 12-14 and 11 (30.5%) in the period 
of gestation 14-16 for Group A and Group B, respectively. The minimum 
number of women was found to be in the gestation period 18-20 for both 
Group A (19.4%) and Group B (16.6%). The mean gestation age was 
15.66 weeks for Group A and 15.61weeks for Group B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Period of gestation of pregnant women 
Weeks Number (%) 
 
Group A (n=36) Group B (n=36) 
12-14 11 (30.5%) 10 (27.7%) 
14-16 09 (25.0%) 11 (30.5%) 
16-18 09 (25.0%) 09 (25.0%) 
18-20 07 (19.4%) 06 (16.6%) 
Mean gestation age 
(weeks) 
15.66 15.61 
 
 
Figure 5. Period of gestation of pregnant women 
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Table 4 & 5 show the relationship of induction-abortion interval to 
the gestational age. Most of the women aborted between 6 and 8 hours 
(36.0%) for oral misoprostol Group-A and 25% for vaginal misoprostol 
Group-B for 12-16 gestational age. For the gestational age of 16-20, the 
maximum number of induced abortion was found to be 13.8% and 16.6% 
for oral misoprostol (Group A) and vaginal misoprostol (Group-B), 
respectively. The mean induction abortion interval (for 12-16 weeks) for 
Group A and Group B was 10.05 and 9.05 h respectively. The mean 
induction abortion interval (for 16-20 weeks) for Group A and Group B 
was 12.43 and 12.52 h respectively. 
 
 
 
 
 
 
 
Table 4. Induction-abortion interval of oral misoprostol (Group-A)  
 
Weeks 
<24 hr  
<48 
hr 
 
Total 
4-6 h 6-8 h 8-10 h 10-12 h 12-16 h 16-24 h 
12-16 
Group A 
 
1 
 
6 
 
4 
 
0 
 
2 
 
1 
 
4 
 
18+(2
*
) 
16-20 
Group A 
 
0 
 
5 
 
3 
 
1 
 
2 
 
1 
 
4 
 
14+(2
*
) 
*Two women each in 12-16 and 16-20 gestation period under Group A 
did not abort. Extra vaginal misoprostol dose was given to make the 
termination complete. 
 
Figure 6. Induction-abortion interval of oral misoprostol (Group-A) 
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Table 5. Induction-abortion interval of vaginal misoprostol (Group B) 
 
Weeks 
<24 hr  
<48 
hr 
 
Total 4-6 h 6-8 h 8-10 h 10-12 h 12-16 h 16-24 h 
12-16 
Group B 
1 9 5 1 2 0 1 19 
16-20 
Group B 
0 7 3 2 3 1 1 17 
 
 
 
Figure 7. Induction-abortion interval of vaginal misoprostol (Group B) 
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4.3. STATISTICAL ANALYSIS 
The induction-abortion rate was calculated for Group A and B for 
gestation of 12-16 and 16-20 (weeks) within 24 hrs and <48 hrs by 
Statistical Analysis. The values are given in the Table 6 & 7.  
Table 6. Induction to expulsion interval for 12-16 gestation weeks 
Time 
 (hrs) 
Frequency of  
(Group A) 
Frequency of  
 (Group B) 
<24 h 14 (70%) 18 (94.73%) 
<48 h 4 (20%) 1(5.26%) 
Total 20 19 
(P<0.05) Fisher exact 2-tailed test, P value = 0.3061  
 
Figure 8. Induction to expulsion interval for 12-16 gestation weeks 
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Table 7. Induction to expulsion interval for 16-20 gestation weeks 
Time 
 (hrs) 
Frequency of  
(Group A) 
Frequency of  
 (Group B) 
<24 h 10 (62.5%) 16 (94.12%) 
<48 h 4 (25.0%) 1(5.88%) 
Total 16  17 
(P<0.05) Fisher exact 2-tailed test, P value = 0.2239  
 
 
Figure 9. Induction to expulsion interval for 16-20 gestation weeks 
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Since the cell values obtained for Group A and B for gestation of 
12-16 and 16-20 (weeks) within 24 hrs and within 48 hrs were less than 5 
and the values in Table No. 6&7 were grouped into a single value. The 
values are given in the Table 8.  The number of women ( in percentage)  
who aborted in the vaginal group was significantly higher than the oral 
group.  It is to be noted that the success rate of group A was 66.67% and 
that of group B was 94.44% within 24 hrs. The induction to expulsion rate 
in the vaginal group was significantly higher than that in the oral 
misoprostol group (P<0.03018).  
 
 
 
 
 
 
 
 
Table 8. Induction to expulsion interval for oral and vaginal groups  
Time 
 (hrs) 
Oral misoprostol 
Group A (n=36) 
Vaginal misoprostol 
Group B (n=36) 
<24 h 24 (66.67%) 34 (94.44%) 
<48 h 8 (22.21%) 2(5.56%) 
Total 32 (4*) 36 
(P<0.05) Fisher exact 2-tailed,  P value = 0.03018  
Statistically significant between the groups 
*Four women in 12-16 and 16-20 gestation period under Group A did not 
abort. Extra vaginal misoprostol dose was given to make the termination 
complete. 
 
Figure 10. Induction- expulsion interval for oral and vaginal groups 
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Table  9 shows the rate of side effects after administration of 
misoprostol.  After misoprostol administration, the women were observed 
hourly for side effects, onset of bleeding and vitals. Maximum number of 
women had nausea (22.2% and 36.1%) for oral misoprostol group (group 
A) and vaginal misoprostol groups (group B), respectively. The 
percentage of women who had abdominal pain was found to be 30.5 and 
33.3 for oral misoprostol group (group A) and vaginal misoprostol groups 
(group B), respectively. Maximum number of women (33.3%) had 
temperature >38
0
C in oral misoprostol group (group A), whereas in 
vaginal misoprostol group (group B), it was only 11.1%. Side-effects such 
as vomiting, diarrhoea, dizziness, headache, breast tenderness and rash 
were not significant in both the groups.  
 
 
 
 
 
 
 
 
 
Table 9. Side effects after misoprostol administration 
Parameter Oral misoprostol 
Group A (n=36) 
Vaginal misoprostol 
Group B (n=36) 
Nausea 8 (22.2%) 13 (36.1%) 
Vomiting 1(2.7%) 0 (0%) 
Diarrhoea 0 (0%) 0 (0%) 
Dizziness 1 (2.7%) 0 (0%) 
Headache 1 (2.7%) 0 (0%) 
Breast tenderness 3 (8.3%) 2 (5.5%) 
Lower abdominal pain 11 (30.5%) 12 (33.3%) 
Temperature>38
0
C 12 (33.3%) 4 (11.1%) 
Rash 1 (2.7%) 0 (0%) 
Values are expressed as number (%) 
 
Figure 11. Side effects after misoprostol administration 
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 4.4. OUT COME OF TREATMENT 
 32 women in oral misoprostol (Group A) and all women in vaginal 
misoprostol (Group B) were successfully induced complete abortion 
(MTP). However, the remaining 4 women in oral misoprostol group 
(Group A) were also given vaginal misoprostol and pregnancy 
termination was completed. 
  
4.5. COMPARATIVE ANALYSIS OF TWO GROUPS OF STUDY 
From the Table No.10, it is understood that the vaginal misoprostol 
was found to be 100 effective in complete expulsion of fetus, whereas in 
oral the termination of pregnancy was complete only in 88.8% of women. 
The remaining (11.2%) women were given additional dose of vaginal 
misoprostol to complete termination. The side-effects due to oral 
misoprostol (11.6%) were more than using vaginal misoprostol (9.5%). In 
case of oral misoprostol (8.3%) the placenta had to be extracted manually. 
However, in case of vaginal route, no such complication was noticed. No 
significant differences in the Pharmacological management of side-effects 
were noted between oral (Group A) and vaginal (Group B).    
 
Table 10. Labour Induction results in two groups 
Parameters Oral misoprostol 
Group A (n=36) 
Vaginal misoprostol 
Group B (n=36) 
 
Complete expulsion (%) 
 
88.8 (n=32) 
 
100 (n=36) 
 
Side-effects (average %) 
 
11.6 
 
9.5 
Pharmacological 
management of side-effects 
(%) 
 
14.0 (n=5) 
 
14.0 (n=5) 
Manual extraction of 
placenta (%) 
 
8.3 (n=3) 
 
0 
Values are expressed as number (%) 
 
 
Figure 12. Labour Induction results in Group A and Group B 
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 In the present study, no women had to undergo medical termination 
of pregnancy by surgical treatment.  No severe complications such as 
heavy bleeding or uterine rupture even in women with previous cesarean 
delivery history were noticed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. DISCUSSION 
Abortion is defined as termination of pregnancy by any means 
before the fetus is viable. In my study, a total of 72 pregnant women of 
>12 and <20 weeks were taken and divided into two groups. Group A 
(n=36) received oral misoprostol whereas Group B (n=36) received 
vaginal misoprostol. 
Misoprostol, while as being accepted as a labour inducing agent, is 
also found to be safe and very effective for the termination of pregnancy 
because of cervical ripening and uterotonic properties. Before 
misoprostol’s widespread use, PGE2, vaginal suppositories and PGF2 
were dominant in the early stage of labour and act mainly on the cervix. 
Even though effective and efficacious, these are associated with side 
effects such as nausea, vomiting, diarrhea and fever in high percentage of 
patients. 
 
 The importance of misoprostol as a cervical ripening agent, in its 
own, is clear. Misoprostol is cheap, less expensive and more convenient to 
administer. It does not require refrigeration for its storage, as it is stable at 
room temperature.  
 
5.1. INDUCTION-ABORTION INTERVAL 
In the present study, most of the women aborted between 6 and 8 
hours (36.0%) for oral misoprostol (Group-A) and 25% for vaginal 
misoprostol (Group-B) for 12-16 gestational age. For the gestational age 
of 16-20, the maximum number of induced abortion was found to be 
13.8% and 16.6% for oral misoprostol (Group A) and vaginal misoprostol 
(Group-B), respectively. 
In this study, four cases of gestation age 16-20, in addition to oral 
misoprostol administration; vaginal misoprostol was administered to 
complete MTP. El-Refaey & Templeton 
[33]
 (1995) and Ashok & 
Templeton 
[34]
 (1999) in their study noticed nearly upto 97% abortion    
within 15 hrs of administration when combination of vaginal and oral 
misoprostol administration was carried out. 
About 80 % of pregnant women aborted within 24 h of misoprostol 
administration. (Suk Wai Ngai et al 2000)
 [11] 
  When the dose of oral 
misoprostol was increased from 200 to 400 µg every 3 h.   
Misoprostol has proven its efficacy as an effective abortifacient for 
the second trimester termination of pregnancy. It is being successfully 
used through all the routes i.e. sublingual, oral and vaginal and in 
different regimens with the induction abortion interval varying from 12 h 
to as high as 33 h.(Wong KS et al. 2000 
[12]   
and Pongsatha S et al., 2001)
 
[14]
.
 
 
Gilbert and Reid 2001
 [13]  
reported higher success rate for vaginal 
administration of misoprostol than oral route (93 vs 19) in mid trimster of 
pregnancy termination. This rate increased within 48 h for vaginal and 
oral groups (100 vs 70% respectively. The dosing regimen in their study 
was 400 µg as the initial dose followed by a second dose of 200 µg 2h 
later and then 4h 200 µg doses until delivery or 32h from commencement 
of treatment. Overall, the average induction to delivery interval in vaginal 
and oral route was more.  
Bebbington  et al  (2002) 
[36]   
used misoprostol orally and vaginally 
for mid trimster of pregnancy. They randomly assigned 140 women. 65 
and 39 women had received misoprostol orally in dose of 200µg every hr 
for 3h and vaginally in dose 400 µg every 4hr, respectievely.  The 
protocol was followed for 24 hr. According to their results, significantly 
more patients were delivered in vaginal group within 24hr (85.50 versus 
39.50%).  
Behrashi M et al. (2008)
 [20]   
 observed in their study that a 
population of sixty healthy women requesting termination of pregnancy 
were randomly divided into two groups. One group received vaginal 
misoprostol and other one received oral misoprostol. In their study, it was 
found that the delivery percentage of vaginal group was significantly 
higher than oral group (86.7 versus 43.30, p value is 0.0006). The 
induction to delivery interval and complication rate in both the groups 
showed no significant and the success rate in vaginal administration was 
higher than the oral group. 
The findings reported by (Mahjabeen et al. 2009) 
[21]
 that sixty 
healthy pregnant women at second trimester of gestation found that after 
oral misoprostol Group-1 (n=30) and vaginal misoprostol Group- 2 (n-30) 
of 200 μg 4 h apart. They found the mean induction abortion interval was 
found to be 11.80±8.30 and 12.80±8.50 h, respectively for the group 1 
and group 2 patients.  The result obtained in his study was insignificant 
statistically. There was no reported cause of diarrhea, dizziness, nausea, 
shivering, pyrexia and hyper stimulation in both the groups.  
Suman R. Shah et al. (2010)
 [23]   
 observed in their study in order to 
find out the safety and effectiveness of vaginal misoprostol for second 
trimester termination of pregnancy, a prospective study involving 30 
women with 12-20 weeks gestation requesting termination was 
conducted. Four hundred microgram misoprostol was inserted in the 
vagina followed by 200μg every four hourly. The mean age of the women 
was 25.96 years. The mean gestational age was 15.66 weeks. Chi-square 
test was used for statistical analysis. 93.3% of women aborted within 16 
hours without any significant side effects. Vaginal misoprostol is a very 
effective and safe method for second trimester pregnancy termination. It 
reduces the time and the cost of second trimester pregnancy termination. 
5.2. ABORTION RATE 
In this study, the vaginal misoprostol was found to be 100 effective 
in complete expulsion of fetus, whereas in oral the termination of 
pregnancy was complete only in 88.8% of women. The remaining 
(11.2%) women were given additional dose of vaginal misoprostol to 
complete termination. The success rate of group A was 66.67% and that 
of group B was 94.44% within 24 hrs. The induction to expulsion rate in 
the vaginal group was significantly higher than that in the oral 
misoprostol group (P<0.03018). The results obtained in my study are 
similar or comparable to the following findings:  
The success rate was found to be 89% within 24 hrs when a regime 
of 200 µg misoprostol was given vaginally at every 12 hr. (Jain and 
Mishell, 1994) 
[37]
.  
Nuutila et al., 1997) 
[38]
. In their study noticed that 200 µg of 
vaginal administration of misoprostol resulted in abortion rates of 40% 
and 92%, in 24 and 48 h respectively.  
Herabutya and O-Prasertsawat (1998) 
[39]
 administered a 200, 400 
and 600 μg misoprostol regimen every 12 h. Abortion success rates over 
48 h were found to be 70.6, 82 and 96%. 
Schaff et al., (1999) 
[40]  
in their comprising of 933 pregnant women 
that  a regimen of misoprostol, 0.80 mg self administered vaginally at 
home after pre-treatment with a regimen of 200 mg of mifepristone 
resulted in 97% complete abortion. There was no significant difference in 
the side effects.  
Kazandi et al . (1999) 
[41]
 administered misoprostol through the 
intravaginal and intracervical routes and an oral combined form. 
Combined use resulted in a 64% abortion rate over 12 h, 80% over 24 h 
and 100% over 48 h. The mean expulsion time was found to be 12.6 ± 
10.4 h. Time to complete the procedure was found to be 9.2 in dead 
fetuses and 19.6 h in live fetuses (p < 0.05).  
Wong KS et al.
 [12]
 (2000) reported short induction-abortion interval 
in trimester pregnancy, when vaginal administration of  misoprostol 400 
ug  every 4 h with the maximum of  5 doses in 24 h was given and it 
resulted in expulsion of live fetus. The complete abortion rate was 80% 
within 24 hrs.  
Feldman et al. (2003) 
[42]
 compared oral and vaginal misoprostol 
for the termination of second trimester pregnancy with different protocol. 
In a randomized clinical trial, all patients received 800 µg of vaginal 
misoprostol and were assigned randomly to receive 400 µg of vaginal 
misoprostol or 400 µg oral misoprostol every 8 h. According to their 
findings, induction time and hospital stay were slightly shorter for oral 
group, however, the difference were not significant. 
In a study conducted by Suneeta Mittal et al. (2005)
[16]
, revealed 
that there was no significant  difference  statistically amongst three groups 
who had   vaginal administration of misoprostol.. Long lasting and 
continuously increasing uterine contractility can be attributed to vaginal 
administration unlike in oral administration of mesoprostol.Gemzell-
Dannielsson K, 1999) 
[43 
 
In another study conducted by Prachasilpchai et al. (2006) 
[44]
, 400 
μg intravaginal misoprostol was administered every 12 h. The success rate 
over 48 h was found to be 89.4% and the mean expulsion time was found 
to be 17.07 ± 9.96 h. Both the success rate over 48 h and the mean 
expulsion time were similar to those of ours. 
Sixty healthy women who were candidates for therapeutic 
termination of pregnancy at second trimester of gestation were recruited 
for the course of study. The grandmultipara, women who had the history 
of hypersensitivity of prostaglandins and scarred uterus were excluded. 
The subjects were assigned into 2 groups. Group-1 (n=30) had 
misoprostol orally, whereas the group-2 (n=30) received the drug by the 
vaginal route. The dosage regimen was similar in both groups that was 
200 μg 4 h apart till the expulsion of fetus or the maximum of  up to 5 
doses.  The main outcome measures of the study were induction expulsion 
interval, need for maternal complications and surgical evacuation. The 
mean induction expulsion interval in Group-1 and 2 was 11.8 ± 8.3 and 
12.8 ± 8.5 hours, respectively, which was not different statistically.  The 
development of expulsion was complete in 53.30% of subject in both 
groups by misoprostol only, whereas 36.60%  required surgical  
evacuation in oral group versus 33.30%  in vaginal group. The rate of 
failed induction in group-1 and 2 was 10% and 13.30%, respectievely. 
(Mahjabeen et al. 2009) 
[21]
. 
Shah Sumant R et al. (2010)
 [23]
 in their study to find out the safety 
and effectiveness of vaginal misoprostol for second trimester termination 
of pregnancy.This is a prospective study involving 30 women with 12-20 
weeks gestation requesting termination. Four hundred microgram 
misoprostol was inserted in the vagina followed by 200μg every four 
hourly.Mean age of the women was 25.96 years. Mean gestational age 
was 15.66 weeks. Chi-square test was used for statistical analysis. About 
93.3% of women aborted within 16 hours without any significant side 
effects. It was concluded that vaginal misoprostol is a very effective and 
safe method for second trimester pregnancy termination. It reduces the 
time and the cost of second trimester pregnancy termination. 
This study conducted by Murat Bozkurt (2012) 
[30]
 involved an 
investigation of the effectiveness and complications of vaginal and oral 
misoprostol use on the termination of second trimester pregnancies. A 
total of 103 cases were recruited from the medical records of the 
Gynecology and Obstetrics Clinic of Taksim Research and Training 
Hospital and Şırnak İdil State Hospital. Women underwent therapeutic 
termination of pregnancy between the 14 to 28th week of gestation using 
the defined combined misoprostol regimen. After the women were 
admitted, 200 μg vaginal (100 μg intracervical, 100 μg into the posterior 
fornix), 200 μg oral doses and 200 μg of sequential doses were 
administered in the 2nd and 4th hour. Subjects were excluded from the 
study if they were out of the defined gestational weeks using additional 
drugs with misoprostol; their data has not been recorded in detail. Of the 
103 cases, 86 had an abortion within 24 h and the mean expulsion time 
was calculated as 15.42 ± 7.14 h (min 6.39 to max 20.03) in this group. 
The success rate for the 24 h was found to be 83.4%. Six more cases had 
an abortion when the second dose was given. The mean expulsion time 
was found to be 9.31 ± 3.26 h (min 6.45 to max 13.21) for the second 24 
h. The success rate over 48 h rose to 89.3%. The total expulsion time was 
18.30 ± 8.74 h. There was a history of previous caesarean sections in 2 
out of 11 cases that did not have an abortion and one of these cases 
underwent a hysterotomy. The pregnancy was terminated by evacuation 
and curettage, as abortion did not occur despite 3 different high dose 
misoprostol regimens as in the other cases. Pregnancies of the remaining 9 
cases were terminated with different misoprostol doses, oxytocin infusion 
and the evacuation and curettage method.  
5.3. INCIDENCE OF SIDE-EFFECTS 
 
In this study, the most common side effects were observed.  After 
misoprostol administration, the women were monitored hourly for vitals, 
side effects and onset of bleeding. Maximum number of women had 
nausea (22.2% and 36.1%) for oral misoprostol group (group A) and 
vaginal misoprostol groups (group B), respectively. The percentage of 
women who had abdominal pain was found to be 30.5 and 33.3 for oral 
misoprostol group (group A) and vaginal misoprostol groups (group B), 
respectively. Maximum number of women (33.3%) had temperature 
>38
0
C in oral misoprostol group (group A), whereas in vaginal 
misoprostol group (group B), it was only 11.1%. Side-effects such as 
vomiting, diarrhoea, dizziness, headache, breast tenderness and rash were 
not significant in both the groups. 
A median dose of about 1000 µg produced vomiting (57%) and 
diarrhoea (29%) in their study of El-Refaey and Templeton (1995). The 
incidence of side effects was not truly associated to total amount of 
misoprostol used. They also observed that side effect of fever was found 
to be 32.4%  and 12.2%  in the group 1 and group 2, respectively. 
Wong et al. 2000 
[12]
 observed in their study that the dosage of 
misoprostol upto 4000 µg over 48hr were tolerated. The side effects were 
solely gastrointestinal and fever but these were soft. 
Javed et al. (2004) 
[45]
 reported nausea and vomiting in 4% of the 
vaginal protocol of the study subjects. Nausea and vomiting was much 
higher in the study of Iqbal, in addition to headache, fever and chills, 
reason of which could be comparatively higher dose (Iqbal et al. 2007) 
[46]
. Gilbert and Reid (2001) 
[13]
 also reported no significant difference in 
side effects between both groups of oral and vaginal misoprostol. 
However, Bebbington et al. (2002) 
[36]
 reported increased febrile 
morbidity in patients who received misoprostol by vaginal route. This 
may be due to high dose of the drug (400 μg) in their study. Dickinson et 
al. (2003) 
[47]
 also noticed more side effects with higher dosage of vaginal 
misoprostol, while Kamal et al. (2005) 
[48]
 reported no significant 
difference between side effects of misoprostol while comparing vaginal 
with oral route.  
The side-effects such as fever (24.5%), abdominal pain (16%), 
nausea and vomiting (5.3%) were noticed (Prachasilpchai et al. 2006)
[44]
.  
 
Behrashi M and Mahdian M (2008) 
[20]
 noticed in their study that in 
vaginal misoprostol group, fever was the most complication (20%) and in 
oral group shivering (33%) and fever (20%) were the most complained. 
Neither of the women in both groups had abdominal pain, vomiting or 
diarrhoea as a side-effect of therapy. Severe complications such as uterine 
perforation and heavy bleeding have not been seen in both groups of 
study. 
 
Helena von Hertzen et al. (2009) 
[22] 
in their study noticed that side 
effects such as chills, shivering and fever were more common in 
misoprostol vaginal administration (28.2%) than in sublingual 
administration (18.5%) and these findings are controversial to some of the 
studies. The more side effects are attributed to the higher concentration of 
serum misoprostol in case of sublingual administration (Tang et al., 
2007). No pharmacokinetics studies have as yet been in print on the 
repeated dose of misoprostol administration when the doses are repeated. 
No significant maternal side effects were noted in both groups. 
Vomiting was reported in one case (3.3%) of vaginal group. However, 
vomiting commenced after starting the oxytocin infusion, therefore, it 
may be due to the side effect of oxytocin (Mahjabeen et al. 2009) 
[21]
 
In the literature, apart from pain, the side effects of misoprostol are 
usually mild and self-limited (Wildschut et al., 2011) 
[49]
. In his study, 
except for pain, complication rates were low and other complications 
except nausea were self-limited. Half of the cases were given antiemetic 
medications for nausea.  
Pongsatha and Tongsong (2011) 
[25]
 found the most common 
complications to be chill (43.7%), analgesic-requiring pain (39.3%) and 
fever (34.3%) in their patients who received 400 μg misoprostol through 
the intravaginal route every 12 h. High doses (800 μg in 24 h) may have 
affected the higher complication rates.  
Herabutya and O-Prasertsawat (1998) 
[50]
 administered a 200, 400 
and 600 μg misoprostol regimen every 12 h. Abortion success rates over 
48 h were found to be 70.6, 82 and 96%. Nausea-vomiting was found to 
be 3.9, 12 and 20%, respectively. Diarrhea rates were 0, 6 and 22%; fever 
rates were 0, 2 and 28% and incomplete abortion rates were 35.3, 28 and 
22%, respectively. In the study conducted by Murat Bozkurt (2012), the 
rate of nausea (11.6%) was found to be similar, fever rate (7.7%) was 
found to be higher however diarrhea rate (1.9%) was found to be lower 
based on the 24 h results. As seen in this study, the success rate increased 
as the dosage increased, however complication rates also increased. 
Severe complications like uterine rupture and mortality were also not seen 
in our study. Of the cases in our study group, 9.7% had a history of 
caesarean sections. Abortion was achieved with this protocol in 80% of 
these cases. The remaining two cases underwent surgical interventions 
like hysterotomy and dilatation and evacuation. Uterine rupture 
complication did not develop in the subjects who had the history of 
caesarean section. 
Minor side effects of pyrexia (3.3%) in each group & nausea & 
vomiting in group A were noticed by Sumera Tahir (2011) 
[28]
 in their 
study, which is comparable to 4%  by Lubna Javed and associates (2004) 
and 0% noted by Jan. E. Dickinson (2003)
 [51]
 . 
Murat Bozkurt (2012) 
[30]
 in his study noted that complication rates 
were fever 7.7%, nausea 11.6% and the combined oral and vaginal use 
was seen to reduce fever incidence however, it increased nausea 
incidence. It is obvious that misoprostol use will lead to abdominal pain 
by causing uterine contractions. Pain is the leading complication 
described in many studies in the literature. However, what was different 
in his study was that analgesic requiring pain was taken as a complication, 
except for abdominal pain, which may be seen in almost every case.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. SUMMARY AND CONCLUSION 
This research study entitled ―Randomized comparative study of 
safety and   efficacy of oral and vaginal misoprostol in the termination of 
second trimester pregnancy over a period of one year at tertiary care 
institution‖ was carried out in the Department of Obstetrics & 
Gynecology, Govt. Kilpauk Medical College Hospital, Chennai. Out of 
122 second trimester pregnant women, 101 were eligible as per the 
inclusion and exclusion criteria. Out of 101 eligible, 72 women were 
randomly selected for two groups (Group A and B) of study. Group A 
comprising of 36 women were given tablet misoprostol 200 µg (Zytotec) 
orally every 4 hrs until the abortion occurred or maximum up to 6 doses.  
Women in Group B were given vaginal misoprostol 200 µg (Zytotec) 
every 4 hrs till the expulsion of fetus or up to a maximum of 6 doses.  
The age distribution and demographic profile of women in Group A 
and B were analyzed. The maximum number of women was found in the 
age group 26-30 (41.6%) and 21-25 (44.4%) for oral (Group A) and 
vaginal (Group B) route of administration, respectively. The maximum 
number of women was found to be multiparous, 77.7% for oral (Group A) 
and 66.6% for vaginal (Group B).  
The maximum number of women was found to be 11 (30.5%) in 
the gestation period 12-14 and 11 (30.5%) in the period of gestation 14-16 
for Group A and Group B, respectively.  
The induction -abortion interval was analyzed. Most of the women 
aborted between 6 and 8 hours (36.0%) for oral misoprostol (Group-A) 
and 25% for vaginal misoprostol (Group-B) for 12-16 gestational age. For 
the gestational age of 16-20, the maximum number of induced abortion 
was found to be 13.8% and 16.6% for oral misoprostol (Group A) and 
vaginal misoprostol (Group-B), respectively.   
The incidence of side effects after administration of Misoprostol 
was briefly studied. After Misoprostol administration, the women were 
observed hourly for side effects, vitals and onset of bleeding. The 
Maximum number of women had nausea (22.2% and 36.1%) for oral 
misoprostol group (group A) and vaginal misoprostol groups (group B), 
respectively. The percentage of women who had abdominal pain was 
found to be 30.5 and 33.3 for oral misoprostol group (group A) and 
vaginal misoprostol groups (group B), respectively. Maximum number of 
women (33.3%) had temperature >38
0
C in oral misoprostol group (group 
A), whereas in vaginal misoprostol group (group B), it was only 11.1%. 
Side-effects such as diarrhea, vomiting, headache, dizziness, rash and 
breast tenderness were not significant in both the groups.   
32 women in oral misoprostol (group A) and all women in vaginal 
misoprostol (group B) were successfully induced complete abortion 
(MTP). However, the remaining 4 women in oral misoprostol group 
(group A) were also given vaginal misoprostol and pregnancy termination 
was completed.  
The comparative analysis for the Group A and B was made to 
evaluate the efficacy of misoprostol by oral and vaginal route of 
administration. The vaginal misoprostol was found to be 100 effective in 
complete expulsion of fetus, whereas in oral, the termination of pregnancy 
was complete only in 88.8% of women. The remaining (11.2%) women 
were given additional dose of vaginal misoprostol to complete 
termination. The success rate of group A was 66.67% and that of group B 
was 94.44% within 24 hrs. The induction to expulsion rate (success rate) 
in the vaginal group was significantly higher than that in the oral 
misoprostol group (P<0.03018). The side-effects due to oral misoprostol 
(11.6%) were more than using vaginal misoprostol (9.5%). In case of oral 
misoprostol (8.3%) the placenta had to be extracted manually. However, 
in case of vaginal route, no such complication was noticed.     
In conclusion, the present research study reveals that vaginal 
misoprostol administration was found to be superior, more effective and 
efficacious in second trimester pregnancy termination than the oral 
administration due to the achievement of complete termination within 48 
h. Shorter hospital stay and less expenditure are the advantages of vaginal 
misoprostol administration. This effect is due to improved 
pharmacokinetics associated with vaginal administration. Moreover, the 
side-effects noticed after vaginal misoprostol administration were 
minimal compared to oral misoprostol administration. In case of oral 
misoprostol administration for some women additional dose of vaginal 
misoprostol administration was warranted. 
It is, therefore, recommended that for the second trimester 
termination pregnancy, it is preferable to use vaginal misoprostol 
administration. 
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ANNEXURE-III 
INFORMATION SHEET 
I am conducting a study on “Randomized comparative study of 
safety and efficacy of oral and vaginal misoprostol in the termination 
of second trimester pregnancy over a period of one year at tertiary 
care Institution” among patients attending Govt. Kilpauk Medical 
College Hospital, Chennai and for that your specimen may be valuable to 
us.  
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared.  
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled.  The results of the special study may be intimated to you at the 
end of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
Signature of Investigator        Signature of Participant 
Date : 
Place : 
ANNEXURE-IV 
PATIENT CONSENT FORM 
Study Detail :‖RANDOMIZED COMPARATIVE STUDY OF SAFETY 
AND   EFFICACY OF ORAL AND VAGINAL 
MISOPROSTOL IN THE TERMINATION OF SECOND 
TRIMESTER PREGNANCY OVER A PERIOD OF ONE 
YEAR AT TERTIARY CARE INSTITUTION” 
 
Study Centre   : Govt. Kilpauk Medical College Hospital, Chennai. 
Patient’s Name  : 
Patient’s Age  : 
Identification NO  : 
Patient may check (√) these boxes 
a. I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction.  
b. I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal rights 
being affected. 
c. I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation to 
it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study.  
d. I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.  
e. I hereby consent to participate in this study.  
f. I hereby give permission to undergo complete clinical examination and 
hematological tests.  
 
Signature/thumb impression               Signature of Investigator 
Patient’s Name and Address:                                              Study Investigator’s 
Name: 
                                                                                                  DR.S.LUIJIM MALA  
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